Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.2
Journals
JPM
Special Issues
Precision Medicine in Hematology–Oncology: Recent Progress and Challenges
share announcement

Precision Medicine in Hematology–Oncology: Recent Progress and Challenges

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Precision Oncology".

Deadline for manuscript submissions: 25 November 2026 | Viewed by 997

Editors

Dr. Anthony M. Hunter

E-Mail Website
Guest Editor
Department of Hematology and Medical Oncology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA
Interests: myeloid neoplasms; myeloproliferative neoplasms; chronic myeloid leukemia; myelodysplastic syndromes; myelodysplastic/myeloproliferative neoplasms; systemic mastocytosis; acute myeloid leukemia; molecular targeted therapies; risk stratification
Special Issues, Collections and Topics in MDPI journals
Dr. Nikolaos Papadantonakis

E-Mail Website
Guest Editor
Department of Hematology and Medical Oncology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA
Interests: myelodysplastic syndromes (MDS); acute leukemias; myeloproliferative neoplasms (MPNs)

Special Issue Information

Dear Colleagues,

Precision medicine has transformed the field of hematology and oncology by enabling tailored therapies based on individual genetic, immune, and clinical profiles. This has led to considerable improvement in outcomes in diseases like leukemia, lymphoma, and myeloma.

This topic aims to highlight advances in genomic profiling, biomarker discovery, and personalized treatment strategies while addressing barriers to equitable implementation across diverse patient populations. By fostering interdisciplinary dialogue among clinicians, researchers, policymakers, and patient advocates, this collection seeks to accelerate the responsible translation of precision oncology from bench to bedside—for all patients, everywhere.

We welcome high-quality original research and comprehensive reviews that address key areas at the forefront of precision hematology-oncology. These include—but are not limited to—advances in genomic diagnostics and bioinformatics, mechanisms of primary and acquired resistance to targeted agents, and real-world evidence demonstrating the impact of precision interventions in routine clinical practice.

Dr. Anthony M. Hunter
Dr. Nikolaos Papadantonakis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oncology
  • hematology
  • precision medicine
  • personalized medicine
  • targeted therapy
  • molecular targets
  • immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

12 pages, 276 KB  
Review
Classic Hairy Cell Leukemia and Related Disorders: An Updated Review of Molecular Features and Personalized Therapies
by Pratik Vijay Shah, Anita Ng, Andrew Shih, Tony Pham, Justin Wang, Houman Khalili, Cho Han Chiang, Adit Singhal, Alix Rosenberg, Sally Ko, Monica Wallin and Douglas E. Gladstone
J. Pers. Med. 2026, 16(6), 276; https://doi.org/10.3390/jpm16060276 - 22 May 2026
Viewed by 758
Abstract
Classic Hairy Cell Leukemia (cHCL) and related conditions are rare, indolent B-cell malignancies characterized by distinctive morphological, immunophenotypic, and molecular features. Over the past decade, major advances in understanding the pathophysiology and molecular underpinnings have reshaped diagnostic and therapeutic approaches. This review synthesizes [...] Read more.
Classic Hairy Cell Leukemia (cHCL) and related conditions are rare, indolent B-cell malignancies characterized by distinctive morphological, immunophenotypic, and molecular features. Over the past decade, major advances in understanding the pathophysiology and molecular underpinnings have reshaped diagnostic and therapeutic approaches. This review synthesizes current knowledge on the cellular origins and signaling pathways that drive cHCL and Hairy Cell Variant (HCL-v)/splenic B-cell lymphoma/leukemia (SBLPN) and other molecular aberrations in disease pathogenesis. We discuss evolving diagnostic modalities, including flow cytometry, immunohistochemistry, and next-generation sequencing, that enhance diagnostic precision and disease monitoring. Additionally, we examine established and emerging therapeutic strategies—from purine nucleoside analogs (PNA) to targeted inhibitors and immunotherapies—that have significantly improved patient outcomes while highlighting challenges such as relapse and treatment resistance. By integrating insights from molecular biology and clinical practice, this review aims to provide a comprehensive understanding of cHCL and related disorders. Full article
(This article belongs to the Special Issue Precision Medicine in Hematology–Oncology: Recent Progress and Challenges)

Other

Jump to: Review

10 pages, 249 KB  
Hypothesis
Perspective for CAR T-Cell Therapy in Underrepresented Populations: A Hypothesis-Generating CD19 Genomic Analysis
by Maysa Al-Hussaini, Anas Al Okaily and Osama Alsmadi
J. Pers. Med. 2026, 16(7), 343; https://doi.org/10.3390/jpm16070343 (registering DOI) - 25 Jun 2026
Abstract
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has fundamentally transformed the treatment landscape for relapsed and refractory B-cell malignancies, yet antigen escape remains a persistent therapeutic challenge that limits long-term remission durability. While antigen loss is typically considered a somatic event acquired during [...] Read more.
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has fundamentally transformed the treatment landscape for relapsed and refractory B-cell malignancies, yet antigen escape remains a persistent therapeutic challenge that limits long-term remission durability. While antigen loss is typically considered a somatic event acquired during tumor evolution under therapeutic selective pressure, germline CD19 polymorphisms could theoretically influence CAR-binding kinetics, alter epitope presentation, and modulate therapeutic outcomes in ways that remain largely not characterized. Unfortunately, Middle Eastern populations are underrepresented in pharmacogenomic databases and CAR-T clinical trials, creating a knowledge gap that may perpetuate global health disparities in access to precision immunotherapy. We analyzed publicly available whole-exome sequencing data from 1196 individuals of Arab origin to comprehensively characterize CD19 variants with potential relevance to CAR T-cell immunotherapy. The L174V (rs2904880) variant stood out, and showed the Valine/Valine (V/V) genotype frequency was 65.3%, corresponding to a V174 allelic frequency of 76.6%, while the minor allele, L174, has a frequency of 23.4%. The missense mutation (c.520C > G) responsible for this variant results in a leucine-to-valine (L174V) substitution at position 174 of the CD19 protein, relative to the reference genome. The cohort genotypes (CC, CG, and GG) exhibited a significant deviation from Hardy–Weinberg equilibrium (p < 0.00001). While this deviation is consistent with the high consanguinity rates (25–60%) amongst Arab populations, it remains not fully explained, and may be attributed to population structure, relatedness, or technical factors. We further emphasize that our computational analysis cannot establish any direct clinical or functional impact due to this variant, and therefore we refrain from suggesting any specific actions at the current time. In light of these findings, we hypothesize that the distinctive genetic architecture of consanguineous populations should not be viewed as a confounding variable. Instead, it presents a unique opportunity to investigate the clinical relevance of germline variation in the context of precision oncology, particularly at therapy-relevant loci, pending functional validation. Full article
(This article belongs to the Special Issue Precision Medicine in Hematology–Oncology: Recent Progress and Challenges)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop